Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 242 of the 244 references it cites were found in a registry or an index.
Abstract
Mitochondria play a central role in a plethora of processes related to the maintenance of cellular homeostasis and genomic integrity. They contribute to preserving the optimal functioning of cells and protecting them from potential DNA damage which could result in mutations and disease. However, perturbations of the system due to senescence or environmental factors induce alterations of the physiological balance and lead to the impairment of mitochondrial functions. After the description of the crucial roles of mitochondria for cell survival and activity, the core of this review focuses on the “mitochondrial switch” which occurs at the onset of neuronal degeneration. We dissect the pathways related to mitochondrial dysfunctions which are shared among the most frequent or disabling neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, Amyotrophic Lateral Sclerosis, and Spinal Muscular Atrophy. Can mitochondrial dysfunctions (affecting their morphology and activities) represent the early event eliciting the shift towards pathological neurobiological processes? Can mitochondria represent a common target against neurodegeneration? We also review here the drugs that target mitochondria in neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial dysfunction has been reported in a number of neurodegenerative diseases [3–6] and correlates with dendritic pathology and synapse disassembly [7–10].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–242 of 242
Demarin, V., Podobnik, S. S., Štorga-Tomić, D., & Kay, G. (2004) · PubMed · Cited by 65
Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole
Ferrari-Toninelli, G., Maccarinelli, G., Uberti, D., Buerger, E., & Memo, M. (2010) · BMC Pharmacology · doi:10.1186/1471-2210-10-2 · Cited by 65
Astaxanthin Protects Primary Hippocampal Neurons against Noxious Effects of A β-Oligomers
Lobos, P., Bruna, B., Cordova, A., Barattini, P., Galáz, J. L., Adasme, T., Hidalgo, C., Muñoz, P., & Paula-Lima, A. (2016) · Neural Plasticity · doi:10.1155/2016/3456783 · Cited by 65
Vaz, A. R., Cunha, C., Gomes, C., Schmucki, N., Barbosa, M., & Brites, D. M. T. O. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8731-8 · Cited by 64
Selvaraju, T. R., Khaza’ai, H., Vidyadaran, S., Mutalib, M. S. A., & Ramachandran, V. (2014) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2014.4.91 · Cited by 62
Tefera, T. W., Wong, Y., Barkl-Luke, M. E., Ngo, S. T., Thomas, N. K., McDonald, T. S., & Borges, K. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161816 · Cited by 61
Banoei, M. M., Houshmand, M., Panahi, M. S. S., Shariati, P., Rostami, M., Manshadi, M. D., & Majidizadeh, T. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9206-5 · Cited by 60 · cited 1×
“Moreover, accumulation of mtDNA defects occurs early in HD to the point of being suggested as a potential biomarker of the disease [82,83].”
BackgroundMedina, S., Martínez, M., & Hernanz, A. (2002) · Free Radical Research · doi:10.1080/107157602100006445 · Cited by 60
Apoptosis‐inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins
Perier, C., Bové, J., Dehay, B., Jackson‐Lewis, V., Rabinovitch, P. S., Przedborski, S., & Vila, M. (2010) · Annals of Neurology · doi:10.1002/ana.22034 · Cited by 58 · cited 1×
“High levels of ROS, due to the high metabolic demand, determine accumulation of toxic oxidative species and structural alterations of complex I, affecting mitochondria functionality in patient brains and mouse models [67,68].”
BackgroundDixit, S., Fessel, J. P., & Harrison, F. E. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.021 · Cited by 58
Pinho, B. R., Duarte, A. I., Canas, P. M., Moreira, P. I., Murphy, M. P., & Oliveira, J. M. A. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.11.021 · Cited by 57
Moss, D. E., Perez, R. G., & Kobayashi, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160733 · Cited by 55
Fukui, H., & Moraes, C. T. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm023 · Cited by 53
An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
Kong, M., Ba, M., Ren, C., Yu, L., Dong, S., Yu, G., & Liang, H. W. (2017) · Oncotarget · doi:10.18632/oncotarget.17622 · Cited by 53
Biological effects of deuteronation: ATP synthase as an example
Olgun, A. (2007) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-4-9 · Cited by 52
Lanni, C., Nardinocchi, L., Puca, R., Stanga, S., Uberti, D., Memo, M., Govoni, S., D'Orazi, G., & Racchi, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010171 · Cited by 50 · cited 1×
“There is a vast literature on the detrimental impact of the accumulation of damage and misfolded proteins inducing dysfunctions at the cellular and mitochondrial level not only in the NS but also in peripheral tissues such as patients fibroblasts [51] which show mitochondrial calcium dysregulation similar to those occ…”
BackgroundSelf-citationJędrak, P., Mozolewski, P., Węgrzyn, G., & Więckowski, M. R. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0308-1 · Cited by 50
Use of FDG PET as an Imaging Biomarker in Clinical Trials of Alzheimer’s Disease
Herholz, K. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.51 · Cited by 47 · cited 1×
“More recently, advanced neuroimaging techniques showed evident metabolic alterations in the brain of AD patients at a very early stage of the disease [44].”
BackgroundPresenilin 2-Dependent Maintenance of Mitochondrial Oxidative Capacity and Morphology
Contino, S., Porporato, P. E., Bird, M., Marinangeli, C., Opsomer, R., Sonveaux, P., Bontemps, F., Dewachter, I., Octave, J.-N., Bertrand, L., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00796 · Cited by 47
Self-citationPilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis
Nicholson, K. A., Chan, J. G. M., Macklin, E. A., Levine, M., Breen, C. T., Bakshi, R., Grasso, D. L., Wills, A.-M. A., Jahandideh, S. S., Taylor, A. A., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.671 · Cited by 47
Bose, A., & Beal, M. F. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14264 · Cited by 47
Pogačnik, L., Ota, A., & Ulrih, N. P. (2020) · Cells · doi:10.3390/cells9030576 · Cited by 47
Protective Effects of Wogonin against Alzheimer’s Disease by Inhibition of Amyloidogenic Pathway
Huang, D.-S., Yu, Y.-C., Wu, C., & Lin, J. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/3545169 · Cited by 45
Dong, S., Huang, X., Zhen, J., Halm‐Lutterodt, N. V., Wang, J., Zhou, C. L., & Yuan, L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1060-6 · Cited by 45
Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate
Weber, J. J., Clemensson, L. E., Schiöth, H. B., & Nguyen, H. P. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.002 · Cited by 45
Shin, E., Nam, Y., Lee, J. W., Nguyen, P.-K. T., Yoo, J. E., Tran, T.-V., Jeong, J. H., Jang, C., Oh, Y. J., Youdim, M. B. H., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9527-1 · Cited by 39
A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology
Stanga, S., Brambilla, L., Tasiaux, B., Dang, A. H., Ivanoiu, A., Octave, J., Rossi, D., Pesch, V. V., & Kienlen‐Campard, P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00384 · Cited by 39
Self-citationPhenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Imindu Liyanage, S., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
Deuterium-depleted water has stimulating effects on long-term memory in rats
Mladin, C., Ciobica, A. S., Lefter, R. M., Popescu, A., & Bild, W. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.037 · Cited by 38 · cited 1×
“Moreover, reduction of deuterium content by DDW ingestion can rescue long-term memory in Wistar rats restoring altered deuterium/hydrogen ratio and enhancing synaptic activity [28].”
BackgroundMaximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives
Khairoalsindi, O. A., & Abuzinadah, A. R. (2018) · Neurology Research International · doi:10.1155/2018/6534150 · Cited by 37
Бачурин, С. О., Махаева, Г. Ф., Shevtsova, E. F., Boltneva, N. P., Ковалева, Н. В., Lushchekina, S. V., Рудакова, Е. В., Dubova, L. G., Vinogradova, D. V., Sokolov, V. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41272-4 · Cited by 37
Fuller, H. R., Gillingwater, T. H., & Wishart, T. M. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.06.004 · Cited by 36
New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
M. Wilkins, H., & K. Morris, J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 35
New Directions in Therapeutics for Huntington Disease
Potkin, K. T., & Potkin, S. G. (2018) · Future Neurology · doi:10.2217/fnl-2017-0035 · Cited by 35
Stanga, S., Zanou, N., Audouard, E., Tasiaux, B., Contino, S., Vandermeulen, G., René, F., Loeffler, J., Clotman, F., Gailly, P. L., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-278739 · Cited by 34
Self-citationDL‑3‑n‑butylphthalide therapy for Parkinson's disease: A randomized controlled trial
Zhou, H., Ye, M., Xu, W., Yu, M., Liu, X., & Chen, Y. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7397 · Cited by 29
Schloesser, A., Esatbeyoglu, T., Piegholdt, S., Dose, J., Ikuta, N., Okamoto, H., Ishida, Y., Terao, K., Matsugo, S., & Rimbach, G. H. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/789710 · Cited by 28
Muscle disorders in childhood.
Dubowitz, V. (1978) · PubMed · Cited by 25
Altered Aconitase 2 Activity in Huntington’s Disease Peripheral Blood Cells and Mouse Model Striatum
Chen, C., Wu, Y., & Chang, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112480 · Cited by 21 · cited 1×
“Moreover, mitochondrial alterations are accompanied by oxidative stress in skin fibroblasts of patients [90]; additionally, the enzymatic activity of the Aco2, which catalyzes the conversion of citrate to isocitrate in the TCA cycle, is impaired in PBMCs of HD patients and PreHD carriers [91].”
BackgroundSmith, E. S., Clark, M. E., Hardy, G. A., Kraan, D. J., Biondo, E., Gonzalez-Lima, F., Cormack, L. K., Monfils, M., & Lee, H. J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.001 · Cited by 20
Dl-3-n-butylphthalide and its emerging beneficial effects in neurology.
Kapoor, S. N. (2012) · PubMed · Cited by 7
Vaidya, S., & Boes, S. (2018) · Quality of Life Research · doi:10.1007/s11136-018-1975-4 · Cited by 1
Cited by
Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease
Misrani, A., Tabassum, S., & Yang, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617588 · Cited by 654
Homocysteine and Mitochondria in Cardiovascular and Cerebrovascular Systems
Kaplan, P., Tatarkova, Z., Sivonova, M. K., Racay, P., & Lehotsky, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207698 · Cited by 196
“of the above-mentioned neurodegenerative and cardiovascular diseases [22].”
BackgroundDeregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria
Gowda, P., Reddy, P. H., & Kumar, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101529 · Cited by 163
Antioxidant Effects of Protocatechuic Acid and Protocatechuic Aldehyde: Old Wine in a New Bottle
Zhang, S., Gai, Z., Gui, T., Chen, J., Chen, Q., & Li, Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6139308 · Cited by 156
“PCA is also regarded as the perfect peroxyl radical scavenger in the polar environment of aqueous solutions and a relatively good anti-radical protector in nonpolar environment of lipid solutions [92].”
BackgroundFields, M., Marcuzzi, A., Gonelli, A., Celeghini, C., Maximova, N., & Rimondi, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043739 · Cited by 156
“[4] determined that mitochondrial dysfunctions represent a crucial point of convergence in the pathogenesis of such neurodegenerative pathologies.”
Background
Metadata
- Authors
- Stanga, S., Caretto, A., Boido, M., & Vercelli, A.
- Affiliations
- Neuroscience Institute Cavalieri Ottolenghi (IT)
- Corresponding author
- Stanga, Serena
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-25
- Volume
- 21
- Issue
- 10
- Pages
- 3719
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7279270
- OpenAlex
- W3026090014
- Cited by
- 90
- References
- 244
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 10 · 2023: 8 · 2022: 18 · 2021: 23 · 2020: 10
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca (“Dipartimenti di Eccellenza 2018–2022” to Department of Neuroscience “Rita Levi Montalcini)
- Fondazione CRT (RF 2017.2052)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- mitochondrial dysfunction, neurodegenerative diseases, neurodegeneration, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, mitochondrial morphology, mitochondrial-targeted drugs, cellular senescence, DNA damage
- MeSH terms
- Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Antioxidants, Organelle Biogenesis, Humans, Mitochondria, Muscular Atrophy, Spinal, Parkinson Disease, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.